Compositions and methods for treating a viral infection may comprise use of an adenoviral vector. An adenoviral vector of the present disclosure may comprise a non-human adenoviral genome with one or more gene locus functionally removed and a transgene. A method of treating a viral infection may comprise administering a composition comprising an adenoviral vector of the present disclosure, to a subject and reducing the infectivity or transmission of the virus. Intranasal administration provides enhance protection of the upper respiratory tract of a subject relative to intramuscular administration.

The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.

Provided are a cell-mediated SARS-COV-2 vaccine and a preparation method therefor, the steps therefor including: the construction of a SARS-COV-2 specific antigen vector presented by stem cells, and the modification and assembly with the stem cells. Two weeks after mouse immunization, approximately 50% of the mice have in vivo antibodies that show a strong positive expression, and the most significant of which being an N-gene modified stem cell vaccine.

The disclosure provides native outer membrane vesicle (NOMV) vaccines containing a coronavirus receptor binding domain (RBD) modified to be a lipoprotein. Also provided are compositions comprising a meningococcal strain having a plasmid-borne gene encoding the SARS-CoV-2 RBD modified to be a lipoprotein. Also provided are a meningococcal strain and a NOMV vaccine containing a plasmid coding for the SARS-CoV-2 RBD with a promoter/enhancer and polyA sequence that provide for expression of the RBD in mammalian cells.

Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.

Technologies for the prevention and/or treatment of pneumococcal infections.

The invention relates to PGT121-germline-targeting designs, trimer stabilization designs, combinations of those two, trimers designed with modified surfaces helpful for immunization regimens, other trimer modifications and on development of trimer nanoparticles and methods of making and using the same.

The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

Mixed allergen compositions of two or more different allergens are provided. In some instances, the mixed allergen compositions include: a nut allergen; an animal allergen; and at least one of: a non-nut plant allergen; a biotic agent; and a vitamin. Also provided are methods of administering the mixed allergen compositions to a subject. The mixed allergen compositions find use in a variety of applications, including health maintenance, immune balance, gut balance, immune support, health improvement and therapeutic applications.

In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.